(Bloomberg) -- Purdue Pharma LP will plead guilty to three felonies and pay $8.3 billion to settle federal probes of how it marketed OxyContin, the highly addictive painkiller blamed for helping spark the U.S. opioid epidemic.The agreement calls for Purdue’s owners, members of the billionaire Sackler family, to make an immediate $225 million payment to the government and for the company to pay $250 million after its bankruptcy is concluded, the U.S. Department of Justice said Wednesday. The remaining amount owed by Purdue will be counted toward the company’s payout to its creditors, court records show.The deal is likely to boost Purdue’s effort to move past claims it helped spark a public-health crisis over opioids with its marketing of OxyContin. Yet the company still faces thousands of civil claims by local and state officials, for which Purdue has previously proposed a $10 billion settlement in bankruptcy court. Governments are seeking reimbursement from Purdue and others for tax dollars spent coping with the crisis, which has led to more than 200,000 U.S. overdose deaths and chronic addiction.“Purdue deeply regrets and accepts responsibility for the misconduct,” Purdue Chairman Stephen Miller said in a statement. “Resolving the DOJ investigations is an essential step in our bankruptcy process. The settlement agreement will pave the way for Purdue to submit a plan of reorganization to the bankruptcy court that will transfer all of Purdue’s assets” to a new company owned by the public, he said.To cope with the tidal wave of claims, Purdue last year filed for Chapter 11 protection in bankruptcy court in New York. U.S. Bankruptcy Judge Robert Drain in White Plains, New York, must approve the settlement with the Department of Justice for it to become final.Sackler family members who served on Purdue’s board “acted ethically and lawfully” in overseeing the company’s operations, and they reached the government deal “to facilitate a global resolution that directs substantial funding to communities in need, rather than to years of legal proceedings,” a family representative said in an emailed statement.As for the criminal charges, “no member of the Sackler family was involved in that conduct or served in a management role at Purdue” during the period under investigation, according to the statement.Read More: How the Sacklers Shifted $10.8 Billion of Their Opioid FortuneDeputy Attorney General Jeffrey Rosen, during a press conference Wednesday, said the settlement with members of the Sackler family resolved their individual civil liability for OxyContin’s wrongful market, but doesn’t bar future criminal prosecution.The company will plead guilty to conspiracy to defraud the U.S. and two counts of conspiracy to violate a federal anti-kickback law. The plea will come at a later date.Federal prosecutors and state and local governments say the company fueled the opioid epidemic with illegal OxyContin marketing.Purdue will admit that from May 2007 to March 2017, it conspired to defraud the U.S. by misleading Drug Enforcement Administration officials about the effectiveness of its opioid-monitoring systems, the Justice Department said.The drugmaker also will admit to conspiring to violate federal kickback statutes by paying sham speaker fees to doctors who ramped up OxyContin prescriptions, the government said. And Purdue will acknowledge illegally making payments to Practice Fusion, an electronic health-records company, in exchange for using the firm’s software to sway doctors into prescribing larger amounts of the opioid-based painkiller and other Purdue drugs, according to the government.Bankruptcy PlanPreviously in bankruptcy court, Purdue had proposed a deal worth more than $10 billion, calling for Sackler family members to hand over the company to a trust controlled by the states, cities and counties that are suing it. As part of that proposal, members of the Sackler family would contribute $3 billion themselves.Numerous state attorneys general, led by Massachusetts Attorney General Maura Healey and New York Attorney General Letitia James, oppose the Sackler’s bankruptcy offer. They want the family to dig into their own pockets for additional billions, and they pledged to continue their own investigations.“DOJ failed,” Healey said in an emailed statement on Wednesday. “Justice in this case requires exposing the truth and holding the perpetrators accountable, not rushing a settlement to beat an election. I am not done with Purdue and the Sacklers.”TransfersA bankruptcy audit last year uncovered $10.4 billion in company transfers engineered by family members since 2008. Some of that money went to offshore trusts and holding companies controlled by the Sacklers. On the eve of the plea’s announcement, Justice Department lawyers urged Drain to limit creditors’ investigations into billions of dollars some members of the Sackler family took out of Purdue.Prosecutors argued in an Oct. 19 letter that forcing family members to hand over to creditors files produced during the Justice Department’s probe of marketing of its opioid-based OxyContin painkiller would provide a disincentive in other cases for targets to cooperate with the government.Purdue has agreed to create a website where it will post for five years some of the documents it previously provided to the government.It’s not the first time Purdue agreed to plead guilty to criminal charges over OxyContin marketing. In 2007, the drugmaker and three of its top executives pleaded guilty to “misbranding” OxyContin, resulting in more than $630 million in civil and criminal penalties -- one of the largest pharmaceutical settlements in U.S. history at the time.As part of that accord, Purdue specifically acknowledged it trained its sales representatives to mislead physicians about opioid risks. The executives were sentenced to community service and served no time in jail.(Updates with comment from Sackler family, Massachusetts attorney general, government press conference.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.